Premium
Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life
Author(s) -
Antonini Angelo,
Tesei Silvana,
Zecchinelli Anna,
Barone Paolo,
De Gaspari Danilo,
Canesi Margherita,
Sacilotto Giorgio,
Meucci Nicoletta,
Mariani Claudio,
Pezzoli Gianni
Publication year - 2006
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20895
Subject(s) - amitriptyline , depression (economics) , sertraline , quality of life (healthcare) , parkinson's disease , medicine , randomized controlled trial , psychiatry , psychology , antidepressant , disease , anxiety , economics , macroeconomics , nursing
Abstract We assessed the effect of 3‐month treatment of sertraline (50 mg) or low‐dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single‐blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS‐17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS‐17 score reduction ≥ 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ‐39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ‐39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self‐perception of motor function and further emphasizes the need for its treatment. © 2006 Movement Disorder Society